Skip to main content

Table 2 Multivariate analysis of treatment effect and selected biomarkers associated with pCR

From: Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Effect

Degrees of freedoma

Odds ratio (95% CI)

Treatment effect

TCH + P (reference; n = 160) versus T-DM1 + P (n = 154)

1

0.68 (0.41–1.12)

PAM50 intrinsic subtypes

Other subtypes (reference; n = 137) versus HER2-E (n = 177)

1

4.02 (2.41–6.70)

HER2 gene ratio

2–4 (reference; n = 71) versus ≥ 4 (n = 243)

1

4.08 (2.12–7.84)

PD-L1 IHC staining subgroups

IC 0 (reference; n = 172) versus IC 1, 2, 3 (n = 142)

1

2.48 (1.48–4.14)

  1. Analysis conducted in patients with no missing covariates
  2. The final logistic model included 314 patients
  3. CI confidence interval, HER2 human epidermal growth factor receptor 2, HER2-E human epidermal growth factor receptor 2-enriched, IC immune cell, IHC immunohistochemistry, PAM50 Prediction Analysis of Microarray with the 50-gene classifier, pCR pathologic complete response, PD-L1 programmed death ligand 1, TCH + P docetaxel, carboplatin, and trastuzumab plus pertuzumab, T-DM1 + P trastuzumab emtansine plus pertuzumab
  4. aDegrees of freedom represent the number of categories used versus the reference
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us